Fonte: The Lancet. Unidade: FMRP
Assuntos: DERMATOPATIAS, MIOSITE
ABNT
RUPERTO, Nicolino et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. The Lancet, v. 387, n. 10019, p. 671-678, 2016Tradução . . Disponível em: https://doi.org/10.1016/s0140-6736(15)01021-1. Acesso em: 11 nov. 2024.APA
Ruperto, N., Pistorio, A., Oliveira, S., Zulian, F., Cuttica, R., Ravelli, A., et al. (2016). Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. The Lancet, 387( 10019), 671-678. doi:10.1016/s0140-6736(15)01021-1NLM
Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, Fischbach M, Magnusson B, Sterba G, Avcin T, Ferriani VPL. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial [Internet]. The Lancet. 2016 ; 387( 10019): 671-678.[citado 2024 nov. 11 ] Available from: https://doi.org/10.1016/s0140-6736(15)01021-1Vancouver
Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, Fischbach M, Magnusson B, Sterba G, Avcin T, Ferriani VPL. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial [Internet]. The Lancet. 2016 ; 387( 10019): 671-678.[citado 2024 nov. 11 ] Available from: https://doi.org/10.1016/s0140-6736(15)01021-1